Cancer treatment – how to wisely reduce its burden? A new ESMO tool to guide de-intensification
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach
How to discuss cancer treatment modulation with patients?
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
Results suggest the efficacy of trastuzumab deruxtecan is influenced by the spatial distribution of HER2 in breast tumour cells
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Combining PARP1 inhibition with an ATR inhibitor does not improve outcomes in pre-treated metastatic TNBC
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Do CDK4/6 inhibitors affect fertility and are they beneficial in premenopausal women?
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status
Ukraine: what help for refugees with breast cancer?
In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved.
Positive patient-reported outcomes data expand on the efficacy benefits of trastuzumab deruxtecan and pembrolizumab
Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer
The future of personalised risk-stratified breast cancer screening
Will widespread screening for breast cancer based on individual risk mean the end of the one-size-fits-all standard mammogram?
Optimising adjuvant treatment in HR+/HER2-negative early breast cancer
Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment